Click for best price
Nonprescription Drugs Market Size, Share 2024
| Market size in 2023 |
US$ 118040 million
|
Forecast Market size by 2030 |
US$ 175010 million
|
| Growth Rate |
CAGR of 5.8% |
Number of Pages |
147 Pages |
This research report provides a comprehensive analysis of the Non-prescription Drugs market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Non-prescription Drugs market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Non-prescription Drugs, challenges faced by the industry, and potential opportunities for market players.
The global Non-prescription Drugs market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Non-prescription Drugs market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Non-prescription Drugs market. Additionally, the growing consumer demand present avenues for market expansion.
The global Non-prescription Drugs market was valued at US$ 118040 million in 2023 and is projected to reach US$ 175010 million by 2030, at a CAGR of 5.8% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The research report on the Non-prescription Drugs market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Non-prescription Drugs market.
Market Overview: The report provides a comprehensive overview of the Non-prescription Drugs market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Brand Drugs, Generic Drug), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Non-prescription Drugs market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Non-prescription Drugs market's trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Non-prescription Drugs market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Non-prescription Drugs market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Non-prescription Drugs market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Non-prescription Drugs market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Non-prescription Drugs, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Non-prescription Drugs market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
- Non-prescription Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Market segment by Application
Global Non-prescription Drugs Market Segment Percentages, By Region and Country, 2023 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Major players covered
- Pfizer
- Roche
- Sanofi
- Johnson & Johnson
- Merck & Co. (MSD)
- Novartis
- AbbVie
- Gilead Sciences
- GlaxoSmithKline (GSK)
- Amgen
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Teva
- Bayer
- Novo Nordisk
- AbbVie
- Takeda
- Boehringer Ingelheim
- Takeda
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-prescription Drugs, market overview.
Chapter 2: Global Non-prescription Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-prescription Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-prescription Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Non-prescription Drugs Market, Global Outlook and Forecast 2024-2030 |
| Market size in 2023 |
US$ 118040 million
|
| Forecast Market size by 2030 |
US$ 175010 million
|
| Growth Rate |
CAGR of 5.8% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
147 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Non-prescription Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-prescription Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-prescription Drugs Overall Market Size
2.1 Global Non-prescription Drugs Market Size: 2023 VS 2030
2.2 Global Non-prescription Drugs Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-prescription Drugs Players in Global Market
3.2 Top Global Non-prescription Drugs Companies Ranked by Revenue
3.3 Global Non-prescription Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-prescription Drugs Companies in Global Market, by Revenue in 2023
3.5 Global Companies Non-prescription Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-prescription Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-prescription Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-prescription Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Non-prescription Drugs Market Size Markets, 2023 & 2030
4.1.2 Brand Drugs
4.1.3 Generic Drug
4.2 By Type - Global Non-prescription Drugs Revenue & Forecasts
4.2.1 By Type - Global Non-prescription Drugs Revenue, 2019-2024
4.2.2 By Type - Global Non-prescription Drugs Revenue, 2025-2030
4.2.3 By Type - Global Non-prescription Drugs Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Non-prescription Drugs Market Size, 2023 & 2030
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Other
5.2 By Application - Global Non-prescription Drugs Revenue & Forecasts
5.2.1 By Application - Global Non-prescription Drugs Revenue, 2019-2024
5.2.2 By Application - Global Non-prescription Drugs Revenue, 2025-2030
5.2.3 By Application - Global Non-prescription Drugs Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Non-prescription Drugs Market Size, 2023 & 2030
6.2 By Region - Global Non-prescription Drugs Revenue & Forecasts
6.2.1 By Region - Global Non-prescription Drugs Revenue, 2019-2024
6.2.2 By Region - Global Non-prescription Drugs Revenue, 2025-2030
6.2.3 By Region - Global Non-prescription Drugs Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Non-prescription Drugs Revenue, 2019-2030
6.3.2 US Non-prescription Drugs Market Size, 2019-2030
6.3.3 Canada Non-prescription Drugs Market Size, 2019-2030
6.3.4 Mexico Non-prescription Drugs Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Non-prescription Drugs Revenue, 2019-2030
6.4.2 Germany Non-prescription Drugs Market Size, 2019-2030
6.4.3 France Non-prescription Drugs Market Size, 2019-2030
6.4.4 U.K. Non-prescription Drugs Market Size, 2019-2030
6.4.5 Italy Non-prescription Drugs Market Size, 2019-2030
6.4.6 Russia Non-prescription Drugs Market Size, 2019-2030
6.4.7 Nordic Countries Non-prescription Drugs Market Size, 2019-2030
6.4.8 Benelux Non-prescription Drugs Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Non-prescription Drugs Revenue, 2019-2030
6.5.2 China Non-prescription Drugs Market Size, 2019-2030
6.5.3 Japan Non-prescription Drugs Market Size, 2019-2030
6.5.4 South Korea Non-prescription Drugs Market Size, 2019-2030
6.5.5 Southeast Asia Non-prescription Drugs Market Size, 2019-2030
6.5.6 India Non-prescription Drugs Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Non-prescription Drugs Revenue, 2019-2030
6.6.2 Brazil Non-prescription Drugs Market Size, 2019-2030
6.6.3 Argentina Non-prescription Drugs Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-prescription Drugs Revenue, 2019-2030
6.7.2 Turkey Non-prescription Drugs Market Size, 2019-2030
6.7.3 Israel Non-prescription Drugs Market Size, 2019-2030
6.7.4 Saudi Arabia Non-prescription Drugs Market Size, 2019-2030
6.7.5 UAE Non-prescription Drugs Market Size, 2019-2030
7 Non-prescription Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Non-prescription Drugs Major Product Offerings
7.1.4 Pfizer Non-prescription Drugs Revenue in Global Market (2019-2024)
7.1.5 Pfizer Key News & Latest Developments
7.2 Roche
7.2.1 Roche Company Summary
7.2.2 Roche Business Overview
7.2.3 Roche Non-prescription Drugs Major Product Offerings
7.2.4 Roche Non-prescription Drugs Revenue in Global Market (2019-2024)
7.2.5 Roche Key News & Latest Developments
7.3 Sanofi
7.3.1 Sanofi Company Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Non-prescription Drugs Major Product Offerings
7.3.4 Sanofi Non-prescription Drugs Revenue in Global Market (2019-2024)
7.3.5 Sanofi Key News & Latest Developments
7.4 Johnson & Johnson
7.4.1 Johnson & Johnson Company Summary
7.4.2 Johnson & Johnson Business Overview
7.4.3 Johnson & Johnson Non-prescription Drugs Major Product Offerings
7.4.4 Johnson & Johnson Non-prescription Drugs Revenue in Global Market (2019-2024)
7.4.5 Johnson & Johnson Key News & Latest Developments
7.5 Merck & Co. (MSD)
7.5.1 Merck & Co. (MSD) Company Summary
7.5.2 Merck & Co. (MSD) Business Overview
7.5.3 Merck & Co. (MSD) Non-prescription Drugs Major Product Offerings
7.5.4 Merck & Co. (MSD) Non-prescription Drugs Revenue in Global Market (2019-2024)
7.5.5 Merck & Co. (MSD) Key News & Latest Developments
7.6 Novartis
7.6.1 Novartis Company Summary
7.6.2 Novartis Business Overview
7.6.3 Novartis Non-prescription Drugs Major Product Offerings
7.6.4 Novartis Non-prescription Drugs Revenue in Global Market (2019-2024)
7.6.5 Novartis Key News & Latest Developments
7.7 AbbVie
7.7.1 AbbVie Company Summary
7.7.2 AbbVie Business Overview
7.7.3 AbbVie Non-prescription Drugs Major Product Offerings
7.7.4 AbbVie Non-prescription Drugs Revenue in Global Market (2019-2024)
7.7.5 AbbVie Key News & Latest Developments
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Summary
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Non-prescription Drugs Major Product Offerings
7.8.4 Gilead Sciences Non-prescription Drugs Revenue in Global Market (2019-2024)
7.8.5 Gilead Sciences Key News & Latest Developments
7.9 GlaxoSmithKline (GSK)
7.9.1 GlaxoSmithKline (GSK) Company Summary
7.9.2 GlaxoSmithKline (GSK) Business Overview
7.9.3 GlaxoSmithKline (GSK) Non-prescription Drugs Major Product Offerings
7.9.4 GlaxoSmithKline (GSK) Non-prescription Drugs Revenue in Global Market (2019-2024)
7.9.5 GlaxoSmithKline (GSK) Key News & Latest Developments
7.10 Amgen
7.10.1 Amgen Company Summary
7.10.2 Amgen Business Overview
7.10.3 Amgen Non-prescription Drugs Major Product Offerings
7.10.4 Amgen Non-prescription Drugs Revenue in Global Market (2019-2024)
7.10.5 Amgen Key News & Latest Developments
7.11 AstraZeneca
7.11.1 AstraZeneca Company Summary
7.11.2 AstraZeneca Business Overview
7.11.3 AstraZeneca Non-prescription Drugs Major Product Offerings
7.11.4 AstraZeneca Non-prescription Drugs Revenue in Global Market (2019-2024)
7.11.5 AstraZeneca Key News & Latest Developments
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Company Summary
7.12.2 Bristol-Myers Squibb Business Overview
7.12.3 Bristol-Myers Squibb Non-prescription Drugs Major Product Offerings
7.12.4 Bristol-Myers Squibb Non-prescription Drugs Revenue in Global Market (2019-2024)
7.12.5 Bristol-Myers Squibb Key News & Latest Developments
7.13 Eli Lilly
7.13.1 Eli Lilly Company Summary
7.13.2 Eli Lilly Business Overview
7.13.3 Eli Lilly Non-prescription Drugs Major Product Offerings
7.13.4 Eli Lilly Non-prescription Drugs Revenue in Global Market (2019-2024)
7.13.5 Eli Lilly Key News & Latest Developments
7.14 Teva
7.14.1 Teva Company Summary
7.14.2 Teva Business Overview
7.14.3 Teva Non-prescription Drugs Major Product Offerings
7.14.4 Teva Non-prescription Drugs Revenue in Global Market (2019-2024)
7.14.5 Teva Key News & Latest Developments
7.15 Bayer
7.15.1 Bayer Company Summary
7.15.2 Bayer Business Overview
7.15.3 Bayer Non-prescription Drugs Major Product Offerings
7.15.4 Bayer Non-prescription Drugs Revenue in Global Market (2019-2024)
7.15.5 Bayer Key News & Latest Developments
7.16 Novo Nordisk
7.16.1 Novo Nordisk Company Summary
7.16.2 Novo Nordisk Business Overview
7.16.3 Novo Nordisk Non-prescription Drugs Major Product Offerings
7.16.4 Novo Nordisk Non-prescription Drugs Revenue in Global Market (2019-2024)
7.16.5 Novo Nordisk Key News & Latest Developments
7.17 AbbVie
7.17.1 AbbVie Company Summary
7.17.2 AbbVie Business Overview
7.17.3 AbbVie Non-prescription Drugs Major Product Offerings
7.17.4 AbbVie Non-prescription Drugs Revenue in Global Market (2019-2024)
7.17.5 AbbVie Key News & Latest Developments
7.18 Takeda
7.18.1 Takeda Company Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Non-prescription Drugs Major Product Offerings
7.18.4 Takeda Non-prescription Drugs Revenue in Global Market (2019-2024)
7.18.5 Takeda Key News & Latest Developments
7.19 Boehringer Ingelheim
7.19.1 Boehringer Ingelheim Company Summary
7.19.2 Boehringer Ingelheim Business Overview
7.19.3 Boehringer Ingelheim Non-prescription Drugs Major Product Offerings
7.19.4 Boehringer Ingelheim Non-prescription Drugs Revenue in Global Market (2019-2024)
7.19.5 Boehringer Ingelheim Key News & Latest Developments
7.20 Takeda
7.20.1 Takeda Company Summary
7.20.2 Takeda Business Overview
7.20.3 Takeda Non-prescription Drugs Major Product Offerings
7.20.4 Takeda Non-prescription Drugs Revenue in Global Market (2019-2024)
7.20.5 Takeda Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Non-prescription Drugs Market Opportunities & Trends in Global Market
Table 2. Non-prescription Drugs Market Drivers in Global Market
Table 3. Non-prescription Drugs Market Restraints in Global Market
Table 4. Key Players of Non-prescription Drugs in Global Market
Table 5. Top Non-prescription Drugs Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Non-prescription Drugs Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Non-prescription Drugs Revenue Share by Companies, 2019-2024
Table 8. Global Companies Non-prescription Drugs Product Type
Table 9. List of Global Tier 1 Non-prescription Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-prescription Drugs Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Non-prescription Drugs Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Non-prescription Drugs Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Non-prescription Drugs Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Non-prescription Drugs Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Non-prescription Drugs Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Non-prescription Drugs Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Non-prescription Drugs Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Non-prescription Drugs Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Non-prescription Drugs Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Non-prescription Drugs Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Non-prescription Drugs Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Non-prescription Drugs Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Non-prescription Drugs Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Non-prescription Drugs Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Non-prescription Drugs Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Non-prescription Drugs Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Non-prescription Drugs Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Non-prescription Drugs Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Non-prescription Drugs Revenue, (US$, Mn), 2025-2030
Table 30. Pfizer Company Summary
Table 31. Pfizer Non-prescription Drugs Product Offerings
Table 32. Pfizer Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 33. Pfizer Key News & Latest Developments
Table 34. Roche Company Summary
Table 35. Roche Non-prescription Drugs Product Offerings
Table 36. Roche Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 37. Roche Key News & Latest Developments
Table 38. Sanofi Company Summary
Table 39. Sanofi Non-prescription Drugs Product Offerings
Table 40. Sanofi Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 41. Sanofi Key News & Latest Developments
Table 42. Johnson & Johnson Company Summary
Table 43. Johnson & Johnson Non-prescription Drugs Product Offerings
Table 44. Johnson & Johnson Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 45. Johnson & Johnson Key News & Latest Developments
Table 46. Merck & Co. (MSD) Company Summary
Table 47. Merck & Co. (MSD) Non-prescription Drugs Product Offerings
Table 48. Merck & Co. (MSD) Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 49. Merck & Co. (MSD) Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Non-prescription Drugs Product Offerings
Table 52. Novartis Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 53. Novartis Key News & Latest Developments
Table 54. AbbVie Company Summary
Table 55. AbbVie Non-prescription Drugs Product Offerings
Table 56. AbbVie Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 57. AbbVie Key News & Latest Developments
Table 58. Gilead Sciences Company Summary
Table 59. Gilead Sciences Non-prescription Drugs Product Offerings
Table 60. Gilead Sciences Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 61. Gilead Sciences Key News & Latest Developments
Table 62. GlaxoSmithKline (GSK) Company Summary
Table 63. GlaxoSmithKline (GSK) Non-prescription Drugs Product Offerings
Table 64. GlaxoSmithKline (GSK) Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 65. GlaxoSmithKline (GSK) Key News & Latest Developments
Table 66. Amgen Company Summary
Table 67. Amgen Non-prescription Drugs Product Offerings
Table 68. Amgen Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 69. Amgen Key News & Latest Developments
Table 70. AstraZeneca Company Summary
Table 71. AstraZeneca Non-prescription Drugs Product Offerings
Table 72. AstraZeneca Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 73. AstraZeneca Key News & Latest Developments
Table 74. Bristol-Myers Squibb Company Summary
Table 75. Bristol-Myers Squibb Non-prescription Drugs Product Offerings
Table 76. Bristol-Myers Squibb Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 77. Bristol-Myers Squibb Key News & Latest Developments
Table 78. Eli Lilly Company Summary
Table 79. Eli Lilly Non-prescription Drugs Product Offerings
Table 80. Eli Lilly Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 81. Eli Lilly Key News & Latest Developments
Table 82. Teva Company Summary
Table 83. Teva Non-prescription Drugs Product Offerings
Table 84. Teva Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 85. Teva Key News & Latest Developments
Table 86. Bayer Company Summary
Table 87. Bayer Non-prescription Drugs Product Offerings
Table 88. Bayer Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 89. Bayer Key News & Latest Developments
Table 90. Novo Nordisk Company Summary
Table 91. Novo Nordisk Non-prescription Drugs Product Offerings
Table 92. Novo Nordisk Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 93. Novo Nordisk Key News & Latest Developments
Table 94. AbbVie Company Summary
Table 95. AbbVie Non-prescription Drugs Product Offerings
Table 96. AbbVie Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 97. AbbVie Key News & Latest Developments
Table 98. Takeda Company Summary
Table 99. Takeda Non-prescription Drugs Product Offerings
Table 100. Takeda Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 101. Takeda Key News & Latest Developments
Table 102. Boehringer Ingelheim Company Summary
Table 103. Boehringer Ingelheim Non-prescription Drugs Product Offerings
Table 104. Boehringer Ingelheim Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 105. Boehringer Ingelheim Key News & Latest Developments
Table 106. Takeda Company Summary
Table 107. Takeda Non-prescription Drugs Product Offerings
Table 108. Takeda Non-prescription Drugs Revenue (US$, Mn) & (2019-2024)
Table 109. Takeda Key News & Latest Developments
List of Figures
Figure 1. Non-prescription Drugs Segment by Type in 2023
Figure 2. Non-prescription Drugs Segment by Application in 2023
Figure 3. Global Non-prescription Drugs Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Non-prescription Drugs Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Non-prescription Drugs Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-prescription Drugs Revenue in 2023
Figure 8. By Type - Global Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 9. By Application - Global Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 10. By Type - Global Non-prescription Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 12. By Application - Global Non-prescription Drugs Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 14. By Region - Global Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 15. By Country - North America Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 16. US Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 20. Germany Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 21. France Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 28. China Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 32. India Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 34. Brazil Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Non-prescription Drugs Revenue Market Share, 2019-2030
Figure 37. Turkey Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Non-prescription Drugs Revenue, (US$, Mn), 2019-2030
Figure 41. Pfizer Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. Roche Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Sanofi Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Johnson & Johnson Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. Merck & Co. (MSD) Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Novartis Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. AbbVie Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Gilead Sciences Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. GlaxoSmithKline (GSK) Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. Amgen Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. AstraZeneca Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 52. Bristol-Myers Squibb Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 53. Eli Lilly Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 54. Teva Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 55. Bayer Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 56. Novo Nordisk Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 57. AbbVie Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 58. Takeda Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 59. Boehringer Ingelheim Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 60. Takeda Non-prescription Drugs Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
